Therapeutic agent for progressive disease caused by increase in Eomes-positive CD4-positive T cells
The present invention provides a therapeutic agent for progressive disease caused by an increase in Eomes-positive CD4-positive T cells, comprising a compound represented by formula (I) or a salt thereof as an active ingredient. In the formula, R 1 is an aldopyranose residue, R 2 is a hydrogen atom or a hydroxy group, R 3 is —CH 2 —, —CH(OH)—CH 2 —, or —CH═CH—, R 4 is a hydrogen atom or CH 3 , x is 0 to 35, and y and z each are an integer satisfying y+z=0 to 3.
1 . A method for treating a progressive disease caused by an increase in Eomes-positive CD4-positive T cells, the method comprising
administering a composition comprising the compound represented by formula (I) or a salt thereof as an active ingredient:
wherein R1 is an aldopyranose residue, R2 is a hydrogen atom or a hydroxy group, R3 is —CH(OH)—CH2—, R4 is a hydrogen atom or CH3, x is 11 to 35, and y and z each are an integer satisfying y+z=0 to 3, and
wherein the progressive disease is progressive relapsing multiple sclerosis, primary progressive multiple sclerosis, or secondary progressive multiple sclerosis.
2 . The method for treating a progressive disease according to claim 1 , wherein the composition is administered orally.
3 . A method for treating a progressive disease caused by an increase in Eomes-positive CD4-positive T cells, the method comprising
administering a composition comprising the compound represented by (25,3S,4R)-1-O-(α-D-galactosyl)-2-(N-tetracosanoylamino)-1,3,4-nonanetriol or a salt thereof,
wherein the progressive disease is progressive relapsing multiple sclerosis, primary progressive multiple sclerosis, or secondary progressive multiple sclerosis.
4 . The method for treating a progressive disease according to claim 3 , wherein the composition is administered orally.
5 . The method according to claim 1 , wherein the progressive disease is progressive relapsing multiple sclerosis.
6 . The method according to claim 1 , wherein the progressive disease is primary progressive multiple sclerosis.
7 . The method according to claim 1 , wherein the progressive disease is secondary progressive multiple sclerosis.
8 . The method according to claim 3 , wherein the progressive disease is progressive relapsing multiple sclerosis.
9 . The method according to claim 3 , wherein the progressive disease is primary progressive multiple sclerosis.
10 . The method according to claim 3 , wherein the progressive disease is secondary progressive multiple sclerosis.